The evolving role of PET-CT in the management of esophageal cancer.
Esophageal cancer, although uncommon in the United States, has been increasing in frequency, and despite advances in therapy, the diagnosis still carries a poor prognosis. Many patients present with locally advanced disease and receive multimodality therapy with combined chemoradiation before surgery. Imaging plays an important role in the initial selection of patients for tri-modality therapy and in evaluating responses to neoadjuvant chemoradiation prior to surgery. There is increasing use of 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in management of esophageal cancer to identify distant metastasis at presentation and to assess response to therapy. Standardized imaging protocols with semiquantitative analysis may also provide prognostic information and be used to individualize patient therapy. This review will discuss the role of imaging studies in the management of esophageal cancer patients, with particular attention to FDG-PET/CT.
Chuang
H H
HH
Department of Nuclear Medicine, University of Texas M. D., Anderson Cancer Center, Houston, TX 77030, USA. chuanghh@mdanderson.org
Macapinlac
H A
HA
D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome